Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.

Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

Lasting survival benefits vs chemotherapy or monotherapy were achieved with nivolumab and ipilimumab for patients MSI-H/ dMMR metastatic colorectal cancer.

Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.

T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

A machine learning model applied to CheckMate 9ER may help predict outcomes and resistance in advanced renal cell carcinoma.

AI Tool May Predict Response, Resistance in Advanced RCC

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

Meeting of the Minds

Training Academy

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

Dr. Jackson is a certified oncology and bone marrow transplant clinical nurse specialist with clinical expertise in hematology/stem cell transplantation/cellular therapy. She is currently unit director–providing oversight of the clinical and fiscal operations of an inpatient hematology unit. Dr. Jackson is also a member of the National Association of Clinical Nurse Specialist, American Asociation of California Nurse Leaders, and the Oncology Nurses Society.

Articles

Oncology nurses are paramount to the success of patients, especially through their work on clinical trials.

The Evolving Role of the Oncology Nurse in Clinical Trials

Gina Mauro currently serves as Vice President of Content at MJH Life Sciences, overseeing 

®. Gina joined the company in 2015 and has held various positions on 

Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Randi Kihnel, MSN, APRN, ACCNS-AG is an advanced practice nurse who works in GI Medical Oncology at Ochsner MD Anderson Cancer Center.

Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.

Case Study: Bridging the Gap for Patients With Metastatic CRC

The FDA approved a perioperative pembrolizumab regimen in head and neck squamous cell carcinoma, marking the first approval in this cancer type in 6 years.

FDA Approves Perioperative Pembrolizumab in Head and Neck SCC

Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

About Us

Editorial Board

Contact Us

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News – Clinical Insights for Cancer Care Nurses

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

The FDA approved darolutamide monotherapy for use in metastatic hormone-sensitive prostate cancer following ARANOTE findings.

Darolutamide Receives FDA Approval for mCSPC

The combination of niraparib with abiraterone acetate and prednisone (AAP) boosted rPFS vs AAP plus placebo in HRR-mutated mCSPC.

Niraparib Plus Abiraterone Improves rPFS in HRR-Mutated mCSPC

The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC lacking HRR mutations.

ODAC Votes Against Talazoparib Combo for Patients With non-HRR mCRPC

Use of the 1.5T Elekta Unity MR-Linac was associated with reduced rates of erectile dysfunction at 6, 12, and 18 months in patients with prostate cancer.

Neurovascular-Sparing Radiation May Reduce ED in Prostate Cancer

Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.

Real-World Data Shows Apalutamide Increases 24-Month OS in mCSPC

Barry Goy, MD, discusses decrease in sexual function and increase in quality of life that may occur with the addition of SADT to EBRT for patients with intermediate-risk prostate cancer.

Barry Goy, MD, discusses benefits and risks of EBRT plus SADT.

Though some factors like sexual function may be negatively affected, the addition of short-term neoadjuvant androgen deprivation therapy (SADT) may increase quality of life (QOL) for patients with intermediate-risk prostate cancer (IRPC), according to an oncologist.

Barry Goy, MD, spoke with Oncology Nursing News about possible adverse effects of SADT at the 

2025 American Society of Clinical Oncology Genitourinary Cancers Symposium

, where his research on external beam radiation therapy (EBRT) in conjunction with SADT was presented.

Goy explained some of the benefits and risks of EBRT and SADT, including alleviating some of the mental burden of a decreased QOL with IRPC. While it may not always be cost-efficient for patients with intermediate or lower risk, he said it may be beneficial for those living with IRPC. Goy is a radiation oncologist at Kaiser Permanente Los Angeles Medical Center.

You always ask the patients in regards to their sexual function. Some patients are still very active, although, for most patients, though, when they have recurrence, it tends to be years later from their initial treatment, so things have changed, maybe, and it may not be as important to them.

So, you know, putting patients on salvage [androgen deprivation therapy] does have some side effects, although by and large, usually it's fairly tolerable.

And the other consideration is a mental consideration, psychologic consideration, because some patients are extremely nervous about their PSA recurrence. So some patients we wind up treating just because mentally, their quality of life goes down…even though it may not kill them.

I don't know if that's the most cost-effective treatment for patients with recurrent prostate cancer, but…those are some of the considerations that I take into account.

This transcript has been edited for clarity and conciseness.

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

Benefits, Risks With EBRT Plus SADT in Intermediate-Risk Prostate Cancer

Michael Lai, ARNP, explained the mechanism of action of PARP inhibitors for the treatment of patients with prostate cancer.

Michael Lai, ARNP, on the mechanism of action of PARP inhibitors for prostate cancer.

In the treatment of prostate cancer, PARP inhibitors can lead to double-strand DNA breaks, thus resulting in cancer death, and expert said.

With prostate cancer cells, PARP inhibitors can selectively target pathogenic DNA damage repair mutations such as 

 to potentially improve the control of a patient’s cancer, said Michael Lai, ARNP, Fred Hutchinson Cancer Center Teaching Associate in the Division of Hematology and Oncology at the University of Washington School of Medicine. Some PARP inhibitors include olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula).

At the recent 8th Annual School of Nursing Oncology, Lai presented on the optimized use of PARP inhibitors in the treatment of patients with prostate cancer. He also spoke with Oncology Nursing News to understand the mechanism of action of PARP inhibitors and how they can further benefit patients.

The PARP inhibitor class of drugs work by inhibiting the PARP protein, which is an enzyme involved in single-strand DNA repair. By inhibiting PARP, this can lead eventually to double-strand DNA breaks.

Now, typically, a normal cell without any issues in its DNA repair will rely on the powerful homologous recombination repair process to address double-strand DNA breaks and perform then the needed DNA damage repair to survive. But if you have a cell with a key mutation in homologous recombination repair, particularly 

, then without this machinery in play, using a PARP inhibitor at that time, thereby also shutting down this avenue for single-strand DNA repair, can essentially open up a lethal vulnerability and result in cancer cell death.

So specifically in prostate cancer cells, we can selectively target those with known pathogenic DNA damage repair mutations like 

, and hopefully better control patients’ cancer.

This transcript has been edited for clarity

Understanding the Mechanism of Action Behind PARP Inhibitors for Prostate Cancer

In the genitourinary cancer space, there have been a lot of updates to follow in the past 5 years. At the 

, a nurse practitioner at Seattle Cancer Care Alliance, about why he thinks there have been so many updates recently.

I think that it's sort of a coalescence of a number of different things, timing, maybe a little bit of luck, and there's just a lot more interest in bladder cancer these days. It's a deadly disease when it's metastatic, and we're trying to find options that go beyond the first and second line that can really prove to have some survival benefit. For prostate cancer, it's such a common ubiquitous disease amongst men, and so, it just makes sense to continue the research in this realm and provide all the options that we can. 

The genitourinary cancer space has seen a lot of updates in the past 5-10 years, but where are they all coming from so suddenly? Oncology Nursing News spoke with Michael Lai, ARNP, a nurse practitioner at Seattle Cancer Care Alliance, about how the genitourinary cancer space has been able to have so many updates recently.

Where New Updates in Genitourinary Cancer Continue to Come From

Prostate cancer tumors tend to be "cold," meaning that they may have difficulty responding to immunotherapy treatment. But combining agents may help improve their responsiveness, explained 

, a nurse practitioner at Seattle Cancer Care Alliance. 

So in prostate cancer, we're looking at, for example, immunotherapy and utilizing this in that context. For immunotherapy, what we're doing right now is, as opposed to doing a single-agent model, using dual agents, because prostate cancer can tend to be a relatively "cold" tumor. So if you use something like docetaxel first or in conjunction with immunotherapies like pembrolizumab (Keytruda) or standard-of-care agents such as abiraterone (Zytiga), the idea is: can we warm up the tumor so that the prostate cancer is more susceptible to immunotherapy agents such as pembrolizumab or others.

Can combining agents turn "cold" prostate cancer tumors "hot"? 

Prostate Cancer

Latest News

Latest Conference Coverage